Serum levels of osteopontin as a prognostic factor in patients with oral squamous cell carcinoma

Tumor Biology

Volumn 35, Issue 4, 2014, Pages 3827-3829

  Mardani, Maryam ^a   Andisheh Tadbir, Azadeh ^b   Khademi, Bijan ^c   Fattahi, Mohammad Javad ^d   Shafiee, Shapour ^a   Asad Zadeh, Maryam ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cytokine; Oral squamous cell carcinoma; Osteopontin

Indexed keywords

OSTEOPONTIN;

ADULT; ARTICLE; BLOOD LEVEL; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ELISA KIT; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; TUMOR GROWTH;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; OSTEOPONTIN; PROGNOSIS;

EID: 84898835302     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1506-4     Document Type: Article

References (20)

1. Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell. 1979;16:885-93.
2. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993;7:1475-82.
3. Wai PY, Kuo PC. The role of osteopontin in tumor metastasis. J Surg Res. 2004;121:228-41.
4. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta (BBA)-Rev Cancer. 2001;1552:61-85.
5. Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK, Kim SK. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2007;57:373-80.
6. Wong TS, Kwong DL, Sham J, Wei WI, Kwong YL, Yuen AP. Elevation of plasma osteopontin level in patients with undifferentiated nasopharyngeal carcinoma. Eur J Surg Oncol Eur Soc Surg Oncol Br Assoc Surg Oncol. 2005;31:555-8.
7. Chiu YW, Tu HF, Wang IK, Wu CH, Chang KW, Liu TY, et al. The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis. Oral Oncol. 2010;46:302-6.
8. Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, et al. A Japanese lung cancer registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol. 2008;3:46-52.
9. Bellahcene A, Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol. 1995;146:95.
10. Takenaka M, Hanagiri T, Shinohara S, Yasuda M, Chikaishi Y, Oka S, et al. Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small-cell lung cancer. Clin Lung Cancer. 2013;14:288-94.
11. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 2004;10:184-90.
12. Eto M, Kodama S, Nomi N, Uemura N, Suzuki M. Clinical significance of elevated osteopontin levels in head and neck cancer patients. Auris Nasus Larynx. 2007;34:343-6.
13. Matsuzaki H, Shima K, Muramatsu T, Ro Y, Hashimoto S, Shibahara T, et al. Osteopontin as biomarker in early invasion by squamous cell carcinoma in tongue. J Pathol Med. 2007;36:30-4.
14. Routray S, Kheur SM, Kheur M. Osteopontin: a marker for invasive oral squamous cell carcinoma but not for potentially malignant epithelial dysplasias. Ann Diagn Pathol. 2013;17:421-4.
15. Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomark Prev. 2004;13:487-91.
16. Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, et al. Co-expression of osteopontin and cd44v9 in gastric cancer. Int J Cancer. 1998;79:127-32.
17. Saitoh Y, Kuratsu J-I, Takeshima H, Yamamoto S, Ushio Y. Expression of osteopontin in human glioma: its correlation with the malignancy. Lab Investig. 1995;72:55-63.
18. Le Q-T, Sutphin PD, Raychaudhuri S, Yu SCT, Terris DJ, Lin HS, et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res. 2003;9:59-67.
19. Hirama M, Takahashi F, Takahashi K, Akutagawa S, Shimizu K, Soma S, et al. Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett. 2003;198:107-17.
20. Liu H, Chen A, Guo F, Yuan L. A short-hairpin RNA targeting osteopontin downregulates mmp-2 and mmp-9 expressions in prostate cancer pc-3 cells. Cancer Lett. 2010;295:27-37.